S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
Log in

NASDAQ:NBIXNeurocrine Biosciences Stock Price, Forecast & News

$116.02
-2.91 (-2.45 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$115.49
Now: $116.02
$118.95
50-Day Range
$118.93
MA: $126.90
$135.15
52-Week Range
$72.14
Now: $116.02
$136.26
Volume661,711 shs
Average Volume838,499 shs
Market Capitalization$10.82 billion
P/E Ratio54.99
Dividend YieldN/A
Beta1.3
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL - Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Read More
Neurocrine Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.96 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$788.10 million
Cash Flow$0.66 per share
Book Value$8.91 per share

Profitability

Net Income$37.01 million

Miscellaneous

Employees585
Market Cap$10.82 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$116.02
-2.91 (-2.45 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

How has Neurocrine Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NBIX stock has increased by 35.1% and is now trading at $116.02.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Neurocrine Biosciences?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neurocrine Biosciences
.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Neurocrine Biosciences
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Monday, August, 3rd. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.16. The company had revenue of $302.40 million for the quarter, compared to analyst estimates of $261.66 million. Neurocrine Biosciences had a return on equity of 39.22% and a net margin of 20.36%. Neurocrine Biosciences's revenue for the quarter was up 64.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.71 earnings per share.
View Neurocrine Biosciences' earnings history
.

What price target have analysts set for NBIX?

19 brokers have issued 12 month price objectives for Neurocrine Biosciences' shares. Their forecasts range from $108.00 to $161.00. On average, they anticipate Neurocrine Biosciences' share price to reach $137.39 in the next year. This suggests a possible upside of 18.4% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences
.

Has Neurocrine Biosciences been receiving favorable news coverage?

Media headlines about NBIX stock have been trending negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Neurocrine Biosciences
.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), Trade Desk (TTD), salesforce.com (CRM) and Walt Disney (DIS).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Mint Tower Capital Management B.V. (8.04%), First Trust Advisors LP (0.92%), Sumitomo Mitsui Trust Holdings Inc. (0.46%), GW&K Investment Management LLC (0.40%), Swiss National Bank (0.37%) and Jennison Associates LLC (0.37%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences
.

Which institutional investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., First Trust Advisors LP, Rhenman & Partners Asset Management AB, Jennison Associates LLC, Candriam Luxembourg S.C.A., UBS Group AG, Russell Investments Group Ltd., and Mutual of America Capital Management LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, and Stephen A Sherwin.
View insider buying and selling activity for Neurocrine Biosciences
.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., Scout Investments Inc., Kornitzer Capital Management Inc. KS, State of Alaska Department of Revenue, Frontier Capital Management Co. LLC, Premier Asset Management LLC, Assenagon Asset Management S.A., and Strs Ohio.
View insider buying and selling activity for Neurocrine Biosciences
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $116.02.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $10.82 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.